The detention of AstraZeneca employees in China for alleged illegal activities, including data privacy breaches and importing unlicensed drugs, directly impacts the company's operations in a market that contributes 13% of its global revenue. This has led to a significant drop in its stock price, reflecting investor concerns over potential legal and regulatory repercussions.